Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2022 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are doing and scaling. Let me analyze the transcript carefully. The key elements needed for a YES answer: 1. Management speaks about counterparties' business as part of its own - describing their ramps, launches, rollouts, etc. 2. The company is already inside that growth, not bidding for it 3. The counterparties' trajectory is early and large relative to the company Let me review what management actually says about their forward outlook: - Greg Trepp discusses their strategic initiatives: e-commerce, global commercial, premium market, home health and wellness, core brands - He mentions new products they're introducing (Quantum Air Fryer, Big Mouth Juice & Blend, portable food warmer, etc.) - He discusses supply chain challenges and inventory - He talks about broad market conditions and consumer demand For the global commercial business, he says "Global commercial sales increased 36%, reflecting continued recovery in the food service and hospitality industries as well as the sale of new products." This is about industry recovery, not specific counterparties' own trajectories. He mentions "We have secured incremental wins as we increase our focus on meeting the needs of global and regional chains." This is about winning business, not about already-embedded growth. For home health and wellness: "Revenue from our new home health and wellness products increased nearly 30% from a very small base as we just introduced new products into this market." He mentions Clorox air purifiers, steam sanitizer, Brita water filtration products coming in 2023, and the injection care management system that "recently became Medicare and Medicaid eligible for certain applications, which is expected to drive increased adoption." He also mentions "recent placements with specialty pharmacies." This last part about the injection care management system - is this narrating a counterparty's trajectory? The Medicare/Medicaid eligibility is a regulatory change, not a counterparty's own build-out. The specialty pharmacy placements are placements, but management doesn't describe those pharmacies' own growth trajectories.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.